Disease-A-Month
Volume 54, Issue 12 , Pages 793-800 , December 2008

Antimicrobial Agents in Treatment of MRSA Infections

References 

  1. Daum RS. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.. N Engl J Med. 2007;357:380–390
  2. Moellering RC. Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46:1032–1037
  3. Gorwitz RJ. The role of ancillary antimicrobial therapy for treatment of uncomplicated skin infections in the era of community-associated methicillin-resistant Staphylococcus aureus.. Clin Infect Dis. 2007;44:785–787
  4. Chamber HF. The changing epidemiology of Staphylococcus aureus.. Emerg Infect Dis. 2001;7:178–182
  5. Kaka AS, Rueda AM, Shelburne SA, et al. Bactericidal activity of orally available agents against methicillin-resistant Staphylococcus aureus.. J Antimicrob Chemo. 2006;58:680–683
  6. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352:1436–1444
  7. Grim SA, Rapp RP, Martin CA, et al. Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.. Pharmacotherapy. 2005;25:253–264
  8. Adra M, Lawrence KR. Trimethoprim/sulfamethoxazole for treatment of severe Staphylococcus aureus infections. Ann Pharmacother. 2004;38:338–341
  9. Proctor RA. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46:584–593
  10. Han LL, McDougal LK, Gorwitz RJ, et al. High frequencies of clindamycin and tetracycline resistance methicillin-resistant Staphylococcus aureus pulsed-field tpe USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol. 2007;45:1350–1352
  11. Ruhe JJ, Menon A. Tetracyclines as an oral treatment option for patients with community onset skin and soft tissue infections caused by methicillin-resistant Staphylococcus aureus.. Antimicrob Agents Chemother. 2007;51:3298–3303
  12. Cenizal MJ, Skiest D, Luber S, et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus.. Antimicrob Agents Chemother. 2007;51:2628–2630
  13. Lewis JS, Jorgensen JH. Inducible clindamycin resistance in Staphylococci: should clinicians and microbiologists be concerned?. Clin Infect Dis. 2005;40:280–285
  14. Martinez-Aguilar G, Hammerman WA, Mason EO, et al. Clindamycin treatment of invasive infections caused by community-acquired, methicillin-resistant and methicillin-susceptible Staphylococcus aureus in children. Pediatr Infect Dis J. 2003;22:593–598
  15. Hageman J, Como-Sabetti K, Rego V, et al. A multistate study of the epidemiology of community-onset methicillin-resistant Staphylococcus aureus [Abstract 121]. 40th Annual Meeting of the Infectious Diseases Society of America, Chicago, October 24-27, 2002. Alexandria, VA: Infectious Diseases Society of America; 2002;
  16. Stevens DL, Ma Y, Salmi DB, et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus.. J Infect Dis. 2007;195:202–211
  17. Centers for Disease Control and Prevention. Staphylococcus aureus resistant to vancomycin: United States, 2002. MMWR Morb Mortal Wkly Rep. 2002;51:565–567
  18. Sakoulas G, Moellering RC. Increasing antibiotics resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis. 2008;46:S360–S367
  19. Hidayat LK, Hsu DI, Quist R, et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138–2144
  20. Peeters MJ, Sarria JC. Clinical characteristics of linezolid-resistant Staphylococcus aureus infections. Am J Med Sci. 2005;330:102–104
  21. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus.. Lancet. 2001;358:207–208
  22. Lam AP, Wunderink RG. Methicillin-resistant S. aureus ventilator-associated pneumonia: strategies to prevent and treat. Sem Resp Crit Care Med. 2006;27:92–103
  23. Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med. 2005;33:1529–1533
  24. Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest. 2003;124:1789–1797
  25. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006;43:180–187
  26. Tally F, Zeckel M, Wasilewski M, et al. Daptomycin: a novel agent for gram-positive infections. Expert Opin Investig Drugs. 1999;8:1223–1238
  27. Mangili A, Bica I, Snydman DR, et al. Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2005;40:1058–1060
  28. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653–665
  29. Silverman JA, Mortin LI, VanPraagh ADG, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis. 2005;191:2149–2152
  30. Pillai SK, Gold HS, Sakoulas G, et al. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother. 2007;51:2223–2225
  31. Cui L, Tominaga E, Neoh H, et al. Correlation between reduced daptomycin susceptibility and vancomycin resistance in Vancomycin-Intermediate Staphylococcus aureus.. Antimicrob Agents Chemother. 2006;50:1079–1082
  32. Cubist Pharmaceuticals. Cubicin (daptomycin for injection) product information. 2003;Lexington, MA
  33. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006;43:518–524
  34. Rodvold KA, Gotfried MH, Cwik M, et al. Serum, tissue, and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother. 2006;58:1221–1229
  35. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46:1683–1693
  36. Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin: a novel lipoglycopeptide for serious gram-positive infections. Expert Opin Investig Drugs. 2007;16:347–357
  37. Cosgrove SE, Fowler VG. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:S386–S393
  38. Micek ST. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2007;45:S184–S190
  39. Kaye KS, Anderson DJ, Choi Y, et al. The deadly toll of invasive methicillin-resistant Staphylococcus aureus infection in community hospitals. Clin Infect Dis. 2008;46:1568–1577

 Disclaimer: The opinions and assertions contained herein are those of the authors and are not to be construed as official or as reflecting the views of the Department of Defense, the Department of the Navy, or the naval services at large.

PII: S0011-5029(08)00116-8

doi: 10.1016/j.disamonth.2008.09.002

Disease-A-Month
Volume 54, Issue 12 , Pages 793-800 , December 2008

Article Tools